Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARDIOVERT: BAY 3670549 in Adult Participants With Atrial Fibrillation
NCT07625215Phase 2Recruiting
- Sponsor
- Bayer
- Start
- Sep 2026
- Primary completion
- May 2030
- Countries
- 8
01
Overview
A Phase 2 trial of BAY-3670549 in Atrial fibrillation (AFib), sponsored by Bayer. Started Sep 2026; status: recruiting.
02
Drugs
BAY-3670549
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT07625215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07625215.